Results 41 to 44 of about 57 (44)

Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations. [PDF]

Int J Mol Sci, 2013
Mebarek S, Abousalham A, Magne D, Do le D, Bandorowicz-Pikula J, Pikula S, Buchet R.   +6 more
europepmc   +1 more source

Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. [PDF]

Chem Rev, 2011
Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G.   +4 more
europepmc   +1 more source

The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors.

Blood, 2007
Payne SG, Oskeritzian CA, Griffiths R, Subramanian P, Barbour SE, Chalfant CE, Milstien S, Spiegel S.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis.

The Journal of rheumatology, 2005
To evaluate the efficacy and safety of a selective inhibitor of secretory phospholipase (sPLA2), LY333013, in the treatment of rheumatoid arthritis (RA).Two hundred and fifty-one patients with active RA despite treatment with one or more disease modifying antirheumatic drugs (DMARD) received oral doses of LY333013 (50, 250, and 1000 mg) or placebo once
John D, Bradley, Alexei A, Dmitrienko, Alan J, Kivitz, Oscar S, Gluck, Arthur L, Weaver, Craig, Wiesenhutter, Stephen L, Myers, Gregory D, Sides   +7 more
openaire   +1 more source